eyes20190129_8k.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): January 23, 2019

 

SECOND SIGHT MEDICAL PRODUCTS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

California

(State or Other Jurisdiction of Incorporation)

 

 

333-198073

 

02-0692322

 

 

(Commission File Number)

 

(IRS Employer Identification No.)  

 

 

12744 San Fernando Road, Suite 400
Sylmar, California 91342

 
  (Address of Principal Executive Offices)  

 

(818) 833-5000

(Registrant's Telephone Number, Including Area Code)

 
 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

-1-

 

 

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 23, 2019, the Compensation Committee of the Board of Directors of Second Sight Medical Products, Inc. (the “Company”) after reviewing the Company’s targeted milestones and performance for the year ended December 31, 2018, approved bonuses for executive and non-executive staff including the following awards to the Company’s named executive officers:

 

Jonathan Will McGuire

President and CEO

  $ 183,913.29  

John Blake

Chief Financial Officer

  $ 66,049.32  

Pat Ryan

Chief Operating Officer

  $ 29,494.16  

 

       The awards are based on the Company’s overall performance in 2018 and the achievement of each executive’s assigned individual milestones, target bonus amount and respective hire dates.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 29, 2019

 

SECOND SIGHT MEDICAL PRODUCTS, INC.

 

/s/ John T. Blake  
By: John T. Blake  
Chief Financial Officer  

 

-2-